BIOMILQ is pioneering the use of human mammary cells to produce bioactive components found in human milk, which are essential for promoting gut, immune, and brain health. The company employs a biomanufacturing process that begins with the collection of breast milk from diverse donors, followed by the isolation and validation of mammary cell lines. These cell lines are then cultivated in bioreactors to generate a range of human milk components. This innovative approach allows BIOMILQ to harness the unique properties of human mammary cells, which have evolved over millions of years to produce a complete array of nutrients and bioactives that positively impact human health.

The technology developed by BIOMILQ addresses the limitations of traditional methods for producing human milk-inspired ingredients, which often rely on bovine or microbial sources that cannot replicate the complexity of human milk. By utilizing human mammary cells, BIOMILQ ensures that the resulting components maintain the bioauthentic structure and activity of natural human milk. This capability not only enhances the nutritional profile of products like infant formula but also opens up new markets for human milk components, positioning BIOMILQ as a leader in human milk research and innovation. The company actively seeks partnerships to further its research, development, and commercialization efforts in this groundbreaking field.

United States

BIOMILQ is a women-owned and science-led mammary biotechnology start-up leveraging its patented technology to produce functional cell-cultured human milk components outside the body. With the goal of bridging the gap between breast milk and infant formula, BIOMILQ aims to revolutionize early-life nutrition by bringing more of the benefits of breast milk to more babies.  

Biomilq

Company Details